within Pharmacolibrary.Drugs.ATC.M;

model M01AX18
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 10 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Feprazone is a non-steroidal anti-inflammatory drug (NSAID) of the pyrazolidinedione class. It has analgesic and anti-inflammatory properties and was previously used in the treatment of conditions such as rheumatoid arthritis and osteoarthritis. Its use has declined and it is not widely approved or used in current clinical practice.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for feprazone in healthy adults due to absence of published pharmacokinetic studies.</p><h4>References</h4><ol><li><p>Berry, DJ, et al., &amp; Parke, DV (1991). The pharmacokinetics of single oral doses of feprazone in healthy volunteers and elderly patients. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 21(9) 1211–1216. DOI:<a href=&quot;https://doi.org/10.3109/00498259109039561&quot;>10.3109/00498259109039561</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1788989/&quot;>https://pubmed.ncbi.nlm.nih.gov/1788989</a></p></li><li><p>Berry, DJ, et al., &amp; Parke, DV (1993). Pharmacokinetics of single oral doses of feprazone in patients with rheumatoid arthritis or with impaired renal clearance. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 23(11) 1231–1240. DOI:<a href=&quot;https://doi.org/10.3109/00498259309059434&quot;>10.3109/00498259309059434</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8310707/&quot;>https://pubmed.ncbi.nlm.nih.gov/8310707</a></p></li><li><p>Berry, D, &amp; Parke, DV (1988). The disposition of feprazone and its hydroxylated metabolite in human volunteers. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 18(7) 857–868. DOI:<a href=&quot;https://doi.org/10.3109/00498258809041724&quot;>10.3109/00498258809041724</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3176523/&quot;>https://pubmed.ncbi.nlm.nih.gov/3176523</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M01AX18;
